Author

H. Baazim

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Assay:metabolomics· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Bergthaler· 2 shared A. Lercher· 2 shared K. L. Bennett· 2 shared P. Majek· 2 shared A. Al-Hakeem· 1 shared A. Bhattacharya· 1 shared A. Ceylan· 1 shared A. G. Erman· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Bergthaler

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

FABP4 as a Therapeutic Host Target Controlling SARS-CoV2 Infection

H. Baazim, E. Koyuncu, G. Tuncman, M. F. Burak, L. Merkel, N. Bahour, E. S. Karabulut, G. Y. Lee, A. Hanifehnezhad, Z. F. Karagoz, K. Foldes, I. Engin, A. G. Erman, S. Oztop, N. Filazi, , G. S. Hotamisligil

This study identifies FABP4 as a host target that modulates SARS-CoV-2 infection, showing that its inhibition reduces viral replication and lung damage in infected hamsters.

bioRxiv · Feb 10, 2024 · PreprintMicrobiology

Ifnar1 signaling breaks the hepatic urea cycle to regulate adaptive immunity

A. Lercher, A. Bhattacharya, A. M. Popa, M. Caldera, M. F. Schlapansky, H. Baazim, P. Majek, J. S. Brunner, L. J. Kosack, D. Vitko, T. Pinter, B. Guertl, D. Reil, U. Kalinke, K. L. Bennett, , A. Bergthaler

This study shows that IFN-I signaling in the liver disrupts the urea cycle, reducing arginine and increasing ornithine, which suppresses CD8 T cell responses and improves liver pathology during viral infection.

bioRxiv · Sep 10, 2019 · PreprintImmunology

The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

L. Kosack, B. Wingelhofer, A. Popa, B. Vilagos, A. Orlova, P. Majek, K. Parapatics, A. Lercher, B. Agerer, A. Ringler, J. Klughammer, M. Smyth, K. Khamina, H. Baazim, D. A. Rosa, , A. Bergthaler

This study identifies the ERBB-STAT3 axis as a driver of Tasmanian devil facial tumor disease and proposes a dual chemo-immunotherapeutic strategy.

bioRxiv · Apr 12, 2018Cancer Biology